News & Events
On June 5, 2017, PathGroup’s clinical laboratory experienced an analytical event on one of the two general chemistry analyzers that caused a negative bias of calcium levels for those test processed on the affected instrument.
For more Information, CLICK HERE
In an ongoing effort to protect the privacy of our shared patients’ protected health information, PathGroup has strengthened our security measures. Beginning Monday,June 5, 2017, all PathGroup electronic client systems including PathConnect, PathGroup Mobile, Result Review, PathSupply and AutoPrint will have a new Single Sign-On system that will strengthen the authentication access. PathGroup’s new password procedures are required by all users.
For more information, please CLICK HERE
Effective April 26, 2017 when completing an Advanced Beneficiary Notice (ABN) in PathConnect, the person responsible for collecting and submitting the ABN will now be prompted to provide a signature upon completion.
For more information, CLICK HERE
Beginning June 5, 2017, all PathGroup electronic client systems including PathConnect, PathGroup Mobile, Result Review, PathSupply and AutoPrint will have a new Single Sign-On system that will strengthen the authentication access. All users will need to comply with PathGroup’s password policies, including requiring users to reset passwords every 60 days.
For More Information CLICK HERE
Brentwood, TN – (Thursday, February 16, 2017) – PathGroup, one of the largest private providers of pathology and laboratory services in the Unites States, is pleased to announce that Pranil K. Chandra, DO, FCAP, FASCP, Vice President and Chief Medical Officer and Medical Director, Genomic and Clinical Pathology Services at PathGroup, will speak at the 2017 Molecular Medicine Tri-Conference in San Francisco, CA on Monday, February 20, 2017.
Dr. Chandra’s session “Garnering Payer Support for Genomic Profiling by Demonstrating Clinical Utility” will review PathGroup’s experience with certain payers in garnering appropriate reimbursement for genomic profiling. In addition, he will review how to demonstrate clinical utility through illustrative examples highlighting diagnostic, prognostic, and/or therapeutic utility across hematologic and solid tumor malignancies.
For more information on the 2017 Molecular Medicine Tri-Conference please visit, http://www.triconference.com
PathGroup is pleased to announce the release of SmartGenomics™ Complete, a pan cancer assay encompassing 160 cancer related genes, 126 gene fusions and whole genome copy number changes via cytogenomic array.
Also included in this major release are five new solid tumor disease specific profiles for use at diagnosis of various malignancies especially for metastatic, aggressive and/or high grade tumors in the following cancer types: Bladder, Breast, Gynecological (including ovarian carcinoma), Prostate and Sarcoma. Additionally, two new hematologic malignancy profiles have been introduced for myeloid neoplasms and lymphoid neoplasms respectively.
Existing SmartGenomics Profiles have also been improved to include the latest relevant assays such as PDL-1 for NSCLC, Her2 for colorectal cancer, gene fusions for thyroid carcinoma and neurological malignancies, copy number support for melanoma, plus other clinically supported additions. Additional information including the genes of interest, fusion partners and profile breakdowns are available by contacting Oncology Customer Support at OncologySupport@pathgroup.com.
Multiple benefits of high-throughput sequencing (commonly referred to as Next-Generation Sequencing or NGS) include: smaller input DNA requirements, greater sensitivity/specificity, advanced bioinformatics processing and rapid turn-around time.
Click HERE for more information.
– Enhanced cancer data and reporting standards for state cancer registries enable structured, real-time, data-driven decision making for cancer treatment specialists and patients
BRENTWOOD, Tenn., (Nov. 29, 2016) – PathGroup, one of the largest private providers of anatomic pathology and clinical lab services in the U.S., today announced a new partnership with the Centers for Disease Control and Prevention (CDC) and the California Department of Public Health that standardizes nationwide state cancer registry data and reporting, enabling physicians, surgeons and researchers to make data-driven treatment decisions with real-time information and analyses.
For Full Release, CLICK HERE
Brentwood, TENN – (November 11, 2016) – PathGroup, one of the largest private providers of pathology services in the Unites States, is pleased to be recognized by The Centers for Disease Control and Prevention (CDC) as the first national laboratory in the United States to standardize and structure cancer pathology and biomarker data reporting from its laboratory information system (LIS) to all state cancer registries.
PathGroup implemented standardized reporting in its proprietary system using the electronic Cancer Checklists (eCC) published by the College of American Pathologists (CAP). State cancer registries across the country will now electronically receive accurate and near real time cancer data.
Click Here to read the entire release from the CDC.
Dr. Pranil K. Chandra, Assistant Vice President and Medical Director of Molecular Pathology and Genomic Medicine Services at PathGroup, has co-authored a publication titled “The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology”.
The Association of Molecular Pathology (AMP) report addresses the challenges in defining the clinical utility of molecular diagnostics for inherited disease and cancer, including molecular diagnostic procedures used for diagnosis, prognosis, risk assessment, prediction of future disease, and monitoring and selection of therapies of disease in patients. The report puts forth clinical utility definitions that appropriately recognize the contribution and value of molecular diagnostic testing to improve patient care.
The report has been released online ahead of publication in the September 2016 issue of The Journal of Molecular Diagnostics. Click Here to read the full manuscript.
Includes New Enhanced Lab Interface Exclusively for PathGroup and digiChart Clients
BRENTWOOD, TENN. – (April 8, 2016) – PathGroup, one of the largest private providers of pathology services in the United States, announced today a unique partnership with digiChart, one of the largest specialty-focused EHR providers in the women’s health space.
PathGroup and digiChart have partnered to develop a new ordering interface that will give the digiChart EHR product full bi-directional lab interface capabilities. PathGroup and digiChart clients will be able to both place orders and receive results through their existing digiChart EHR, creating a seamless process that will both save time in the office and simplify the lab ordering workflow for their practice. “PathGroup is committed to providing our clients with superior service. We have always been a leader in utilizing technology to deliver fast, accurate results and this partnership with digiChart adds ease of ordering for our mutual clients to that equation,” stated Dan Valenti, Senior Vice President and Chief Information Officer at PathGroup.
“As one of the largest providers of women’s health services in the United States, PathGroup wanted an EHR partner that showed that same commitment to women’s health providers. We felt that by working together, PathGroup and digiChart could significantly enhance and simplify the workflow for our mutual clients, helping them ultimately better serve their patients,” stated Richard Halstead, Executive Vice President and Chief Commercial Officer at PathGroup.
Built by OB/GYNs for OB/GYNs, digiChart’s specialty-focused EHR mimics the workflow in the OB/GYN practice, improves clinical decision-making, and provides unique functionality to enhance patient care. “This partnership with PathGroup significantly enhances our lab interface capabilities, allowing our clients’ offices to quickly and easily order and receive results for all their lab testing needs, directly in their digiChart EHR,” stated Rodney Hamilton, M.D., Chief Executive Officer at digiChart. digiChart also provides revenue cycle management tools that integrate seamlessly with the EHR, providing faster, more accurate processing of claims.
PathGroup and digiChart look forward to further enhancing the partnership with future collaborations, focused on ensuring clients have services that benefit both their practice and their patients.
About PathGroup
Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services, as well as one of the largest providers of Women’s Health services in the United States. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service. For more information, visit www.pathgroup.com.
About digiChart
digiChart offers specialized tools, services, and education to help OB/GYN practices compete with the larger practices or hospitals seeking to control more of the care continuum. Our tools deliver value clinically, operationally, and financially providing insight to know how to make the right changes to keep your practice on course. digiChart has expanded its offering to enhance the foundational EHR with new medical billing services and practice analytics to give OB/GYN practices the resources needed to succeed. Improving the Practice of Women’s Health. For more information, visit digiChart.com.
Contact:
Brent Sower
AVP Marketing
PathGroup
615.234.3908
bsower@pathgroup.com
Kathy Gill
VP Marketing and Communications
digiChart, Inc.
615.481.6646
kgill@digichart.com
